Brief: Bayer - Askbio Announces Completion Of Enrollment In Phase 2 Clinical Trial Of AB-1002
April 1 (Reuters) - BAYER AG BAYGn.DE: ASKBIO ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF AB-1002 INVESTIGATIONAL GENE THERAPY FOR HEART FAILURE Further company coverage: [BAYGn.DE] (Gdansk Newsroom) ((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)